Deciphering translational and transcriptional impairment in Roberts syndrome

Baoshan Xu,Tania Bose,Karin Zueckert-Gaudenz,Madelaine Gogol,Jennifer Gerton
DOI: https://doi.org/10.1096/fasebj.28.1_supplement.1138.6
2014-01-01
The FASEB Journal
Abstract:Roberts Syndrome (RBS) is an autosomal recessive disease characterized by prenatal growth retardation caused by mutations in the cohesin acetyltransferase ESCO2 gene. Previously we revealed that mutations in human ESCO2 impaired ribosomal RNA production and protein synthesis. We recently observed mTOR (mammalian target of rapamycin) signaling was strongly downregulated in RBS cells. Stimulation of the mTOR pathway with L‐leucine helped to partially rescue both protein synthesis and cell proliferation. To further address the transcriptional and translational deficits in RBS and their response to L‐leucine, we are performing ribosome profiling to monitor translation in vivo by deep sequencing of ribosome‐protected mRNA fragments. Western blot analysis shows that a number of 40S and 60S ribosome subunits are reduced in the RBS cells. Remarkably, global 5’TOP (5′terminal oligopyrimidine tract) mRNA translation, including 79 ribosome proteins and a panel of eukaryotic translation initiation factors, and most PRTE (Pyrimidine Rich Translational Element) genes show improved translation in RBS cells treated with the mTOR stimulant L‐leucine. The different expression of hundreds of genes is rescued with L‐leucine, suggesting the differential gene expression could be translation‐driven. In conclusion, our results uncover transcriptional and translational mechanisms that contribute to the etiology of RBS. Grant Funding Source : Supported by Stowers Institute and Cornelia de Lange Syndrome Foundation Research Grants
What problem does this paper attempt to address?